BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 6804562)

  • 21. Immune rejection of metastases arising from intraocular tumors in mice.
    Niederkorn JY; Knisely TL; Mayhew E
    Invest Ophthalmol Vis Sci; 1986 Sep; 27(9):1355-61. PubMed ID: 3091527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of anterior chamber-associated immune deviation by corneal allografts placed in the anterior chamber.
    Yamada J; Streilein JW
    Invest Ophthalmol Vis Sci; 1997 Dec; 38(13):2833-43. PubMed ID: 9418737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic restrictions and cellular interactions in the induction of anterior chamber associated immune deviation (ACAID).
    Ferguson TA; Kaplan HJ
    Reg Immunol; 1988; 1(1):62-8. PubMed ID: 2978943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anterior chamber associated immune deviation induced by TNP-splenocytes (TNP-ACAID). I. Systemic tolerance mediated by suppressor T-cells.
    Waldrep JC; Kaplan HJ
    Invest Ophthalmol Vis Sci; 1983 Aug; 24(8):1086-92. PubMed ID: 6192107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anterior chamber-associated immune deviation promotes corneal allograft survival.
    Niederkorn JY; Mellon J
    Invest Ophthalmol Vis Sci; 1996 Dec; 37(13):2700-7. PubMed ID: 8977485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of tumor necrosis factor receptor expression in anterior chamber-associated immune deviation (ACAID) and corneal allograft survival.
    Niederkorn JY; Mayhew E; Mellon J; Hegde S
    Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2674-81. PubMed ID: 15277491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of anterior chamber-associated immune deviation with lymphoreticular allogeneic cells.
    Okamoto S; Hara Y; Streilein JW
    Transplantation; 1995 Feb; 59(3):377-81. PubMed ID: 7871568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histopathologic analysis of intraocular allogeneic tumors in mice.
    Luckenbach MW; Streilein JW; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1985 Oct; 26(10):1368-76. PubMed ID: 3930419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intraocular injection of class II-restricted peptide induces an unexpected population of CD8 regulatory cells.
    Kosiewicz MM; Streilein JW
    J Immunol; 1996 Sep; 157(5):1905-12. PubMed ID: 8757308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD4+PD-1+ T cells acting as regulatory cells during the induction of anterior chamber-associated immune deviation.
    Meng Q; Yang P; Li B; Zhou H; Huang X; Zhu L; Ren Y; Kijlstra A
    Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4444-52. PubMed ID: 17003438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of cyclosporine on anterior chamber-associated immune deviation with retinal transplantation.
    Ishioka M; Okamoto S; Streilein JW; Jiang LQ
    Invest Ophthalmol Vis Sci; 1997 Sep; 38(10):2152-60. PubMed ID: 9331279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose cyclophosphamide inhibits anterior chamber-associated immune deviation (ACAID) and the production of extracellular antigen-specific T cell proteins induced by trinitrophenylated (TNP) spleen cells.
    Wang Y; O'Rourke J; Cone RE
    Cell Immunol; 1995 Oct; 165(2):284-8. PubMed ID: 7553893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alloantigen presentation to the anterior chamber of the eye subverts specific in vitro cell-mediated immune responses.
    Whittum JA; Niederkorn JY; Streilein JW
    Transplantation; 1982 Oct; 34(4):190-5. PubMed ID: 6183804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors.
    Knisely TL; Luckenbach MW; Fischer BJ; Niederkorn JY
    J Immunol; 1987 Jun; 138(12):4515-23. PubMed ID: 3108394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of eye-derived tolerance does not depend on naturally occurring CD4+CD25+ T regulatory cells.
    Keino H; Takeuchi M; Kezuka T; Hattori T; Usui M; Taguchi O; Streilein JW; Stein-Streilein J
    Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):1047-55. PubMed ID: 16505040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Requirement of CD80+ costimulation for rejection of ocular tumors and termination of immune privilege.
    Chen PW; Uno T; Ksander BR
    Exp Eye Res; 2006 Sep; 83(3):574-83. PubMed ID: 16643898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
    Chen PW; Ksander BR
    Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The immune response and the eye: a role for TNF alpha in anterior chamber-associated immune deviation.
    Ferguson TA; Herndon JM; Dube P
    Invest Ophthalmol Vis Sci; 1994 Apr; 35(5):2643-51. PubMed ID: 8163352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of anterior chamber-associated immune deviation (ACAID) on rat islet allograft rejection.
    Koevary SB; Beaudry K
    Ocul Immunol Inflamm; 2000 Mar; 8(1):39-47. PubMed ID: 10806433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spontaneous immune rejection of intraocular tumors in mice.
    Niederkorn JY; Meunier PC
    Invest Ophthalmol Vis Sci; 1985 Jun; 26(6):877-84. PubMed ID: 3924853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.